Many cases are referred to immunology and allergy units for investigation of possible food allergies after presentation to emergency departments. The timing of reactions in respect to food consumption is crucial in deciding whether this is a likely cause. Acute food reactions will mostly be immediate or within two hours of eating, and only rarely occur after longer times. Urticarial or angioedematous reactions the next day will not be connected with food ( Table 1 ).
The lesions of urticaria are usually caused by histamine, released by mast cells. While this can be due to immunoglobulin E (IgE)-mediated phenomena, it can also be triggered by neurogenic reflexes and by direct stimulation, for example by opiates or strawberries. Angioedema, however, is caused mainly by the release of bradykinin, through activation in the fluid phase of the kinin cascade. Infection and trauma are potent triggers for kinin production. This explains the link between ACE-I and angioedema: the drugs inhibit the breakdown of bradykinin, but if there is no source of bradykinin in the first place then no angioedema will occur. Hence there must be another significant bradykinin-producing event before angioedema will occur. Patients may therefore have been on the drug for many years without problems before the angioedema occurs. Once it has happened however, it is advisable to discontinue the drug and substitute an angiotensin-II receptor-blocking drug (ARB), which have similar cardiovascular benefits but do not interfere with bradykinin metabolism. Leukotriene and complement breakdown products are also involved in persistent lesions of both urticaria and angioedema. A small proportion of patients may have autoantibodies, including antibodies against the IgE receptor on mast cells; such patients may have particularly persistent urticaria that is difficult to control without recourse to immunosuppressive agents. Urticarial vasculitis is associated with antibodies against complement C1q, which lead to persistent complement activation: low C1q and C3 and C4 will be found.
Hereditary angioedema (HAE) due to C1-esterase inhibitor deficiency is an autosomal dominant condition. A total of 90% of cases are due to type I with low or absent C1-esterase inhibitor levels; the remaining 10% are due to point mutations in the active site of the enzyme which lead to high or high normal levels of C1-esterase inhibitor but low or absent function.
2 A third type of HAE is due to gain-of-function mutations in clotting factor XII; this is extremely rare. Attacks of HAE are often triggered by trauma, infections, stress, pregnancy, and the use of hormonal contraceptives. In contrast to other types of angioedema, the attacks are slow to develop. Urticaria occurs only rarely. Attacks may affect any part of the body but may affect the larynx (this is less common with other types of angioedema) and may affect the bowel, presenting to surgeons as an acute abdomen. Surgery should be avoided if at all possible, unless there is very clear evidence of pathology separate from abdominal angioedema. Recurrent laparotomy is unhelpful to the patient. CT scanning may identify bowel oedema. Idiopathic angioedema is more likely to present in the night or on waking, possibly due to pH changes in serum overnight. Presentation on waking (after a prolonged fast) makes it extremely unlikely that foods are involved.
Acquired angioedema (AAE) is usually seen in an older group of patients and is typically associated with splenic villous lymphoma (the spleen will be enlarged) or with myeloma. The paraprotein contains anti-C1-esterase inhibitor activity (tests are available at reference centres for this). The angioedema may precede the overt development of the lymphoma. Similar autoantibodies against C1-esterase inhibitor can be seen very rarely in systemic lupus erythematosus.
Patients who describe cold urticaria fall into two types: most commonly it is straightforward physical urticaria, and an ice cube test will be positive (see below); much rarer is familial cold autoinflammatory syndrome (FCAS), associated with defects in the gene encoding cryopyrin. Here the cold-induced urticaria is associated with headaches, systemic malaise, rigors, conjunctivitis, and arthralgia. Often other family members are also affected.
DIAGNOSIS AND TESTING
Diagnosis is dependent on the nature of the lesions. If nothing is visible at the time of the consultation, encourage the patient to take photos (mobile phones are a huge medical benefit) to document the appearance. The lesions of urticarial vasculitis typically last in one place for more than 24 hours and often fade, leaving brown discoloration. A biopsy will confirm the presence of vasculitis if there is doubt. A careful history and full examination is required, with particular attention to teeth, sinuses, gallbladder and liver, spleen, and lymph nodes, as these are sites of potential unrecognised 
MANAGEMENT
The management of urticaria and angioedema depends to a certain extent on the underlying cause. Correctable causes should be treated. Low iron stores, even if the haemoglobin and mean corpuscular volume (MCV) are normal may be enough to trigger urticaria, so replacement of iron is always indicated and reasons for low iron (menstrual loss, diet, and malabsorption [e.g. coeliac disease]) should be sought. Infection should be identified and treated.
The basis of management of urticaria is long-acting, non-sedating antihistamines. Sometimes a simple switch to a different non-sedating antihistamine may be helpful. Fexofenadine has a higher strength tablet (180 mg) licensed for use in urticaria. The dose of non-sedating antihistamines may need to be above those recommended in the British National Formulary (BNF). Cetirizine, for example, may be used in doses up to 60 mg/day in divided doses and fexofenadine up to 720 mg/ day in divided doses. These dosage regimes are unlicensed. Current antihistamines have been checked for cardiovascular safety. Older antihistamines have been associated with torsade de pointes ventricular arrhythmia, subsequently found to be due to interference with cardiac potassium channels. Sedating antihistamines chlorphenamine and hydroxyzine should only be used at night. Tricyclic antidepressants have useful antihistaminic properties and can be effective, particularly where stress is a major contributor. They are, however, sedating. Anti-H2 drugs may be added and can occasionally help.
Cimetidine is preferred because it also has immunosuppressive properties. Leukotriene antagonists such as montelukast and zafirlukast are also recommended as second-line agents, but rarely seem to be effective. Mirtazapine can be very effective. Calcium channel blockers can also be beneficial. The approach to stepped care is outlined in Table 2 .
Corticosteroids should be used only as emergency doses for acute events. Chronic steroid therapy is to be avoided as subsequent withdrawal is difficult, with severe flares the rule.
Immunosuppressive drugs may be used. Ciclosporin may be valuable, as it also inhibits basophils and mast cell degranulation. Tacrolimus is an alternative. Urticarial vasculitis may respond to hydroxychloroquine, colchicine, dapsone (check glucose-6-phosphate dehydrogenase deficiency [G6PD] first), sulphasalazine, or methotrexate. All of these drugs require regular blood monitoring. Annual eye checks are required for people taking hydroxychloroquine (due to the risk of retinal damage). Omalizumab is undergoing clinical trials and may be Topical therapies such as doxepin cream, which has potent anti-H1 and anti-H2 antihistaminic activity, or menthol in aqueous cream, which provides marked cooling through its effect on local nerves can provide some symptomatic relief.
Angioedema not due to HAE or AAE may respond to antihistamines, but if it does not and no cause is identified, prophylaxis with tranexamic acid is effective (with monitoring of liver function and liver ultrasound).
Modified androgens such as danazol and stanozolol are potential alternatives but are poorly tolerated in women, because of the androgenic effects (which will affect all women) and have much greater risks of liver toxicity, particularly hepatocellular carcinoma, the risk of which increases with duration of therapy.
Angioedema due to HAE can be prevented with tranexamic acid or modified androgens. If attacks are frequent or severe, then prophylaxis with intravenous C1-esterase inhibitor is appropriate, but must be given weekly. Acute attacks can be treated with intravenous C1-esterase inhibitor or with icatibant, a bradykinin B2 antagonist, which is administered subcutaneously. The latter will also be licenced for other types of angioedema in 2014 All such patients must be under the care of an immunologist or allergist as indicated in the guidance for specialist commissioning in the NHS.
Adrenaline is only required where there is clear evidence of systemic symptoms (hypotension, laryngeal obstruction, bronchospasm). Patients should not be given adrenaline for self-injection unless they have had severe systemic symptoms.
Where there is a poor response to the highest levels of treatment, continually re-evaluate the patient for alternative diagnoses. Consider the use of psychological therapies.
Patients with cold-induced urticaria need to be warned not to expose large areas of skin to sudden cooling as this can trigger massive and lethal histamine release: this includes swimming or winter sports.
CONCLUSIONS
The key points are as follows: the commonest causes of chronic spontaneous urticaria are stress, infections and other medical problems. IgE-mediated allergy is a rare cause of chronic spontaneous urticaria. Hereditary angioedema is a rare cause of spontaneous angioedema. ACE-inhibitors are a common cause of angioedema without urticaria. High dose antihistamines are preferable to corticosteroids for management of urticaria.
Highlights
• The commonest cause of chronic urticaria is stress. • Physical urticaria may be a marker of underlying medical problems and stress. • Chronic urticaria is rarely due to 'allergy' and allergy tests are not necessary. • Angioedema is caused by excessive bradykinin release; ACE inhibitors prevent the breakdown of bradykinin.
•
The mainstay of management of urticaria is treatment with long-acting non-sedating antihistamines if necessary in increased doses (unlicensed indication).
• Corticosteroids should only be used for acute not chronic treatment.
